Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsAddiction psychiatry — stimulant and methamphetamine use

Psych MEQs / SAQs · Addiction psychiatry — stimulant and methamphetamine use

Stimulant and methamphetamine use — acute MAP to definitive care (MEQ)

FRANZCP-style MEQ on methamphetamine-associated psychosis, acute stabilisation, withdrawal, contingency management, limited pharmacotherapy (ADAPT-2 or mirtazapine), and dual diagnosis.

20 marks20 min2 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 31-year-old man is brought by police after smashing a neighbour's window. He has smoked crystal methamphetamine for 72 hours. He is tachycardic and hypertensive but afebrile and oriented. He believes the neighbour is beaming laser surveillance into his flat and hears a third-person commentary. CK is mildly elevated; ECG shows sinus tachycardia without ischaemic ST change. (i) Define MAP and contrast it with primary psychotic disorder using timeline discriminators. (ii) Outline immediate medical and behavioural priorities. (iii) Describe the expected methamphetamine withdrawal time course and a key psychiatric risk in the crash. (iv) Give an evidence-based definitive treatment package for stimulant use disorder, naming the strongest psychosocial modality and accurately stating one limited pharmacotherapy option with dose if offered. (v) State dual-diagnosis and disposition principles. (20 marks)

Model answer

Reveal model answerShowHide

(i) MAP definition and discriminators. Methamphetamine-associated psychosis is a syndrome of delusions and/or hallucinations temporally linked to methamphetamine use, often with clear consciousness. Dose-related association with heavier use periods is established. Primary psychotic disorder is favoured when symptoms persist substantially after verified abstinence, premorbid decline or strong family history emerges, or longitudinal course diverges from use intensity. Day-one labelling of lifelong schizophrenia after a single binge is premature; equally, substance induction does not mean no treatment.[2]

(ii) Immediate priorities. Medical: observations, ECG already done — continue cardiac and metabolic monitoring; manage hypertension/tachycardia per emergency protocols; trend CK; exclude evolving ACS, hyperthermia, stroke. Behavioural: low-stimulus environment, de-escalation, oral medication first if needed, IM only if required under local rapid-tranquillisation guidance; avoid unnecessary restraint. Dangerous psychosis: time-limited antipsychotic after medical screen; violence/suicide risk documentation; legal status under local statute principles.[1]

(iii) Withdrawal course and crash risk. After binge cessation: early crash with fatigue/hypersomnia; peak dysphoria, anhedonia, irritability and craving around day 2; improvement over about 1–2 weeks with residual sleep/mood symptoms possible. Not typically seizure-dominant like alcohol, but suicide risk in the crash requires active safety planning.[3]

(iv) Definitive package. Psychosocial first-line per specialty guidance: contingency management (strongest signal), CBT/CRA, Matrix-style multi-element care, harm reduction, housing, sexual health. No methadone-equivalent licensed standard. Limited pharmacotherapy examples if specialist-context: mirtazapine 30 mg nocte (trial regimens) or naltrexone XR 380 mg IM every 3 weeks + bupropion XL 450 mg daily (ADAPT-2) with exclusions/monitoring — never presented as universal mandatory cure.[1][4][5]

(v) Dual diagnosis and disposition. Treat psychosis and stimulant use concurrently; do not withhold care for perfect abstinence. Disposition by risk: observation/inpatient if high violence or suicide risk; else shared community mental health + AOD follow-up with early review as crash evolves.[1]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]ASAM/AAAP Clinical Guideline Committee The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder J Addict Med, 2024.PMID 38669101
  2. [2]McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study JAMA Psychiatry, 2013.PMID 23303471
  3. [3]McGregor C, Srisurapanont M, Jittiwutikarn J, et al. The nature, time course and severity of methamphetamine withdrawal Addiction, 2005.PMID 16128721
  4. [4]Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder N Engl J Med, 2021.PMID 33497547
  5. [5]Pfund RA, Ginley MK, Boness CL, et al. Contingency Management for Drug Use Disorders: Meta-Analysis and Application of Tolin's Criteria Clin Psychol (New York), 2024.PMID 38863566
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousStigma, recovery and rights-based care (MEQ)Professional — stigma, recovery and rights-based careNextStimulant intoxication and withdrawal — MAP, toxicity, and anti-craving vacuum (MEQ)Addiction psychiatry — acute stimulant syndromes